...
首页> 外文期刊>Leukemia and lymphoma >Hematopoietic stem cell transplantation in peripheral T-cell lymphomas.
【24h】

Hematopoietic stem cell transplantation in peripheral T-cell lymphomas.

机译:外周T细胞淋巴瘤的造血干细胞移植。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Peripheral T-cell lymphomas (PTCL) are a rare entity with a dismal outcome. After conventional chemotherapy they showed a worse prognosis compared with B-cell non-Hodgkin's lymphoma (NHL), except for anaplastic lymphoma-kinase (ALK)-positive anaplastic large cell lymphomas (ALCL). High-dose chemotherapy followed by autologous stem cell transplantation (SCT) has been evaluated in relapsed patients as well as in the upfront setting. Available data showed an advantage for patients who received transplant as first line treatment whereas results of autografting at relapse have been satisfactory only for ALK-positive ALCLs compared to other PTCL subtypes. Based upon preliminary results, allogeneic SCT can be also considered as an alternative strategy in these lymphomas. Whether or not the postulated graft-versus-lymphoma effect may overcome the poor prognosis of T-cell NHL patients has to be established.
机译:外周T细胞淋巴瘤(PTCL)是一种罕见的实体,其结果令人沮丧。常规化疗后,除间变性淋巴瘤激酶(ALK)阳性的间变性大细胞淋巴瘤(ALCL)外,与B细胞非霍奇金淋巴瘤(NHL)相比,它们的预后更差。已对复发患者以及前期患者进行了大剂量化疗后进行自体干细胞移植(SCT)的评估。现有数据显示,对于接受一线移植治疗的患者而言,其优势在于,与其他PTCL亚型相比,复发时自体移植的结果仅对ALK阳性的ALCL令人满意。根据初步结果,同种异体SCT也可被视为这些淋巴瘤的替代策略。必须确定假定的移植物抗淋巴瘤的作用是否可以克服T细胞NHL患者的不良预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号